Abstract
Introduction
It has been more than 35 years since tau was first discovered as a protein that co-purified with microtubules through cycles of assembly and disassembly and was named for its ability to induce 'tubule' formation [1] . Two years later it was noted that tau was a phosphoprotein [2] , and in 1984 it was demonstrated that tau in a more dephosphorylated state promotes microtubule assembly with greater efficiency, thus assigning a regulatory function to its phosphorylation [3] . Although these were intriguing findings at the time, interest in tau remained only moderate until it was demonstrated that tau made up the paired helical filaments which form the neurofibrillary tangles (NFTs) found in Alzheimer disease (AD) brain, and the tau that formed these filaments was abnormally phosphorylated [4] [5] [6] [7] [8] . These findings catapulted tau into the ) in which there was pronounced tau pathology but no A␤ pathology [18, 19] . Following these findings, a growing list of sporadic neurodegenerative tauopathies marked by abnormal tau-containing lesions in the brain and without significant A␤ pathology, were characterized [20] . These findings strongly suggested that alterations in tau could result in neurodegeneration and hinted at the importance of tau in the pathogenic processes in AD. This idea was further supported by the finding that neurons in which tau had been knocked out were relatively resistant to A␤-induced cell death compared to neurons from wild-type mice expressing normal tau levels [21] .
In 1998, it was first discovered that mutations in the tau gene caused rare autosomal dominant neurodegenerative diseases (collectively known as frontotemporal dementia with parkinsonism linked to chromosome 17

It is now very clear that tau plays a critical role in the pathogenesis of AD. However, it is also becoming evident that NFTs are not the 'toxic' tau species but rather non-aggregated forms are likely the culprits. For example, in an inducible tauopathy model, attenuating expression of FTDP-17 mutant tau ameliorated behavioural deficits and neuronal loss although NFT numbers either remained unchanged or increased [22]. More recent studies have shown that knocking out tau significantly attenuates A␤-induced behavioural deficits but does not affect A␤ levels in an APP mouse model of AD [23], and that A␤-induced deficits in axonal transport do not occur in neurons from tau
-/-mice [24] . [25, 26] . [27, 28] . Given that abnormal phosphorylation is the most prominent modification of tau in AD brain, and truncation of tau also seems likely to play a key role in the evolution of tau inclusions, we will discuss these two modifications a bit further prior to exploring the role of tau in AD pathogenesis. 
These and other findings have contributed to a re-evaluation of the role of tau in neurodegeneration, including the consideration of a dual or synergistic relationship between tau and A␤ in AD pathogenesis
In this review, we will first present a brief overview of pathological modifications of tau and what may be the toxic species, followed by an overview of how tau is cleared from the cell and deficits that may occur in AD brain. We will then discuss possible targets of pathological tau that may contribute to disease progression and finally end with a presentation of potential 'tau-centric' therapeutic strategies for the treatment of AD.
Pathological modifications of tau
A defining feature of AD brain is tau pathology. Many different posttranslational modifications of tau in AD brain have been described including phosphorylation, nitration, glycosylation, glycation, ubiquitylation and truncation
Tau phosphorylation
Tau is a phosphoprotein and phosphorylation plays a prominent role in regulating its physiological function. It is also clear that aberrant tau phosphorylation occurs in AD brain and is associated with pathogenesis. Previous reviews have provided full discussions of the kinases and phosphatases that
Tau truncation
During the evolution of tau pathology in AD brain, tau appears to undergo sequential cleavage events [52] . Caspases, which are apparently elevated in AD brain [53] [54] [55] , are likely involved in the proteolytic processing of tau. Several years ago it was shown that tau is cleaved by caspases at aspartic acid 421 (D421) in AD brain and appeared to be generated early in the pathogenic process [56, 57] . Tau truncated at D421 is more fibrillogenic than full length tau [56, 57] and early studies suggested that tau truncated at D421 significantly increased cell death [58, 59] [67] .
In addition to being cleaved by caspases at D421, tau may also be cleaved at D13 and D402 in AD brain by caspase 6 [68] [69] [70] [75, 76] . Although this concept is supported by data from other neurodegenerative disease cell models [77, 78] 
Tau toxicity in Alzheimer disease
Although for many years 'A␤-centric' hypotheses dominated AD research [17] [118] [119] [120] , which has been replicated in experimental models exhibiting A␤ and tau pathologies [25, [121] [122] [123] [124] [125] [126] . Abnormalities exist in mitochondrial fission/fusion and respiration protein levels in AD brain [120, 127] , which may explain mitochondrial morphological alterations observed in several areas of AD patient brains [118] and apparent deficits in energy metabolism observed via PET scan [128] . [124, 125] [25, 126] . This suggests that tau may exert its toxicity through mitochondria, and may permit or facilitate A␤-induced mitochondrial damage. Figure 1 summarizes some of the possible targets of pathological forms of tau.
Interestingly, stable expression of D421 truncated tau in cortical cell lines induced fragmentation of mitochondria [65], possibly replicating the imbalance of mitochondrial fission and fusion in AD brain. Reductions in several components of the tricarboxylic acid (TCA) cycle and the oxidative phosphorylation (OXPHOS) system have also been reported in AD transgenic mouse models
Potential 'tau-centric' therapeutic strategies
There is a growing interest in developing pharmacological agents directed at pathological forms of tau. These treatment strategies 
Fig. 1 Cellular targets of toxic tau. (A) Tau undergoes phosphorylation in physiological conditions. However, in pathological conditions, tau becomes hyperphosphorylated and/or cleaved, which facilitates aggregation and increases the toxicity of tau. In the continuum of the aggregation process, pathologically modified tau monomers first form oligomers, which further aggregate into fibrils and finally into NFTs. Recent studies suggest that monomeric or oligomeric species of tau are the more toxic than aggregated forms [22]. (B) Tau may manifest its toxicity by enabling or facilitating A␤-induced excitotoxicity, mitochondrial damage and/or by disrupting axonal transport. Pathological tau may participate in the localization of Fyn kinase to the post-synaptic compartment, where it phosphorylates NMDAR subunits, causing increased inward Ca 2ϩ conductance and leading to excitotoxicity [106]. Tau also contributes to mitochondrial dysfunction (i.e. decreased ⌬m, increased ROS, fragmentation) [65] and disrupts anterograde axonal transport of mitochondria and possibly other synaptic elements by binding to JIP1, which regulates the binding of cargos to the kinesin motor complex
Tau aggregation inhibitors
It is well established that the NFT load can be used as a marker to clinically classify the stages of disease progression [129] . Also, the amount and progression of NFTs correlates positively with the extent of cognitive impairment [130] . [132] . Therefore in this review we will just highlight a few key studies. Methylene blue is a phenothiazine that, along with other phenothiazine derivatives, has been used to treat a number of different medical conditions [133] . One important effect of methylene blue is the inhibition of aggregation of proteins that take on ␤-sheet conformation in vitro, including tau [134, 135] [137] .
N3 is a benzothiazole derivative that has been shown to protect against tau aggregation and tau-mediated neurodegeneration concurrent with neuroprotection in an in vivo model [138] . [139] .
Based on in vitro assays, it was proposed that N3 was a direct tau fibrillization inhibitor and that this mechanism contributed to its neuroprotective effects. However, further studies demonstrated that N3 disrupts the binding of tau filaments to Thioflavin S, but does not directly antagonize the formation of tau fibrils. These studies again strongly suggest that the neuroprotective effects of the compound are not due to a reduction in tau aggregation
Taken together, the results of these and other studies suggest that the reduction of tau fibril formation in vitro by certain small molecules may not be related to their therapeutic effects in vivo.
Microtubule stabilizing agents
Given that, in AD brain, tau is hyperphosphorylated and less functional as a microtubule stabilizer, therapies that compensate for this loss of tau function and stabilize microtubules are being considered. A reduction in microtubule integrity has been proposed to be an important factor in synaptic dysfunction [140] . In brain slice preparations a derivative of the microtubule stabilizing agent taxol protected against synaptic loss in response to lysosomal stress [140] . These findings are of interest, but unfortunately these taxolbased derivatives often show low blood-brain barrier permeability [141] . However, intranasal administration of an octapeptide (NAP), which stabilizes microtubules, in an AD mouse model reduced both tau and A␤ pathology indicating that it has therapeutic potential [142] . In addition, brain penetrant microtubule-stabilizing compounds have been identified which may allow for an in vivo analysis of the efficacy of this type of approach in the treatment of AD in appropriate animal models [141] . [146] . A study from another group also demonstrated that immunization of other tauopathy mouse models with phospho-tau peptides also reduced tau pathology without significant side effects [147] . However, an earlier study found that immunization of mice with full length recombinant tau resulted in neurological deficits with neuropathology [148] . Given this finding and the fact that an active immunization protocol with A␤ resulted in an adverse response in a number of the human cases [149] , it would seem that a passive immunization protocol may be a better therapeutic approach. In addition, the optimal AD relevant form of tau to be targeted for immunotherapy needs to be considered. Although the studies cited above focused on phospho-tau, there is a growing awareness that oligomeric tau forms may be the more toxic species, and therefore would make an appropriate target for tau immunotherapy [144] . In a recent study, relatively pure, homogenous populations of neurotoxic tau oligomers were prepared [150] , thus providing a potential immunogen for the generation of antibodies to prefilament forms of tau.
Tau immunotherapy
Finally, there is a growing awareness that pathological forms of tau, as well as other disease relevant proteins such as ␣-synuclein (Parkinson's disease) and mutant huntingtin (Huntington's disease) may be capable of being spread from cell to cell and thus facilitate disease progression [151] [152] [153] [154] . In addition, extracellular tau may also induce toxicity. Therefore, it has been proposed that extracellular tau may be a potential target for immunotherapy in the future [155] .
Autophagy activators
Reducing the burden of aggregated proteins through up-regulation of autophagy has been proposed as a potential therapeutic approach for various neurodegenerative diseases [156] . Numerous studies have focused on the use of rapamycin, a well characterized clinically approved drug that up-regulates autophagy through inhibition of the central regulatory protein mammalian target of rapamycin (mTOR) . In cell models, rapamycin mediates the reduction of aggregates composed of both polyglutamine and polyalanine expansions [157, 158] . In Drosophila models expressing wildtype or mutant forms of tau, rapamycin reduced toxicity and it was suggested that this was due to a reduction in insoluble tau [158] . Rapamycin also reduced both A␤ and tau pathology in the 3xTg AD mouse model, though it is unclear in this study if reductions of tau pathology occur as a direct result of rapamycin treatment, or as a downstream effect of A␤ reduction [159] . Though [163] . In addition, the disaccharide trehalose (found in multiple non-mammalian organisms) has been shown to reduce both mutant huntingtin aggregate burden and accumulation of mutant ␣-synuclein in an mTORindependent manner [164] . Trehalose also promoted the clearance of phosphorylated and aggregated tau in a mouse model that was both parkin-null and expressed tau with multiple FTDP-17 mutations [165] . Concurrent with decreases in tau pathology, the study described improvements in behavioural deficits, as well as decreases in both astrogliosis and dopaminergic neuron death [165] . The findings of the above studies are quite promising, though further study of additional pharmacological effects of mTOR-independent autophagy is needed. [167, 168] . However, conflicting results exist as to the efficacy of these antioxidants in AD patients, which in part may be due to differences in study design and the characteristics of the subjects [169] . Ubiquinone is an important component of the electron transport chain that can act as a potent lipid oxidant scavenger. Therapeutic ubiquinone has shown positive results in animal models of AD and Parkinson's disease [170, 171] and appears to show some efficacy in clinical trials with Parkinson's disease [172, 173] and Huntington's disease [174, 175] transport chain [176] 
Mitochondria targeted therapies
